Loading...
Market
Will clinical trials for monoclonal antibodies against A. baumannii show positive results by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press release or publication from Cambridge University or related research institutions
Story
Researchers Develop Monoclonal Antibodies Against A. baumannii to Combat Antimicrobial Resistance
Sep 17, 2024, 09:00 AM
Researchers are exploring the use of monoclonal antibodies as a potential solution to tackle antimicrobial resistance, which could make infections untreatable in the future. Scientists at Cambridge University, including those at the Baker Lab, have developed monoclonal antibodies that show effectiveness against drug-resistant infections, specifically using engineered mice against A. baumannii. Prof. Stephen Baker highlighted the potential of this approach as a powerful new weapon. Additionally, machine-learning models for monoclonal antibody allocation during pandemics could reduce hospital cases by a third by targeting at-risk patients and those who would benefit most from treatments. This method may also alleviate reliance on broad-spectrum antimicrobials for treating infections.
View original story
Similar markets
Yes • 50%
No • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trials halted • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%